Namal P. M. Liyanage
Immunology and Microbiology · The Ohio State University
Publications
72
Citations
892
Est. group size
~47
Recurring co-author estimate
Active years
24
Publishing since 2003
Namal P. M. Liyanage's research focuses on understanding immune responses during infections such as HIV/SIV and studying vaccine candidates aimed at preventing or reducing the risk of these infections in preclinical animal models. Work spans immune cell dynamics in tissues, vaccine adjuvant effects, and antibody responses, primarily using non-human primate models of HIV (SIV/SHIV). The lab also studies related topics such as immune cell depletion strategies and, in some studies, viral spillover between animals and humans.
Publication output has grown substantially over the last decade, rising from a couple of papers per year in 2017-2018 to a peak of 12 in 2022, with continued strong output (averaging about 6 papers/year over the last 5 years).
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Innate adaptive immune cell dynamics in tonsillar tissues during chronic SIV infection
Frontiers in Immunology · 2023
- SARS‐CoV‐2 infection of companion animals in Egypt and its risk of spillover
Veterinary Medicine and Science · 2022
- Comparison of CD3e Antibody and CD3e-sZAP Immunotoxin Treatment in Mice Identifies sZAP as the Main Driver of Vascular Leakage
Biomedicines · 2022
- CD3e-immunotoxin spares CD62L <sup>lo</sup> Tregs and reshapes organ-specific T-cell composition by preferentially depleting CD3e <sup>hi</sup> T cells
bioRxiv (Cold Spring Harbor Laboratory) · 2022
- CD3e-immunotoxin spares CD62Llo Tregs and reshapes organ-specific T-cell composition by preferentially depleting CD3ehi T cells
Frontiers in Immunology · 2022
- Anti-V2 antibodies virus vulnerability revealed by envelope V1 deletion in HIV vaccine candidates
iScience · 2021
- Engagement of monocytes, NK cells, and CD4+ Th1 cells by ALVAC-SIV vaccination results in a decreased risk of SIVmac251 vaginal acquisition
PLoS Pathogens · 2020
- Expression of CD40L by the ALVAC-Simian Immunodeficiency Virus Vector Abrogates T Cell Responses in Macaques
Journal of Virology · 2020
- Correction: ALVAC-HIV B/C candidate HIV vaccine efficacy dependent on neutralization profile of challenge virus and adjuvant dose and type
PLoS Pathogens · 2020
- Anti-V2 Antibodies Virus Vulnerability Revealed by Envelope V1 Deletion in HIV Vaccine Candidates
SSRN Electronic Journal · 2020
- Role of Tonsillar Innate and Adaptive immune cells during SIV infection in Rhesus macaques
The Journal of Immunology · 2020
- ALVAC-HIV B/C candidate HIV vaccine efficacy dependent on neutralization profile of challenge virus and adjuvant dose and type
PLoS Pathogens · 2019
- Schifanella SHIVC All Data.xlsx
Figshare · 2019
- HIV vaccine candidate activation of hypoxia and the inflammasome in CD14+ monocytes is associated with a decreased risk of SIVmac251 acquisition
Nature Medicine · 2018
- Stool antigen immunodetection for diagnosis of Giardia duodenalis infection in human subjects with HIV and cancer
Journal of Microbiological Methods · 2017
- The Journal of Immunology×8
- Nature Medicine×4
- Frontiers in Immunology×4
- bioRxiv (Cold Spring Harbor Laboratory)×4
- PLoS Pathogens×3
- Li Pan
Immunology and Microbiology · The Ohio State University
- Kai Yang
Immunology and Microbiology · Indiana University
- John Guardiola
Immunology and Microbiology · Indiana University
- Mario Alles
Immunology and Microbiology · The Ohio State University
- Anthony G. Mansour
Immunology and Microbiology · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile